watch
Biogen Idec, Inc.

Biogen Idec, Inc.

Sector: Biological Products Except Diagnostic Substances Region: MA, United States


: | Nasdaq: BIIB


Similar to: Bebra Biogas Holding AG, NPS Pharmaceuticals, Inc., BioTime, Inc.

Biogen Idec, Inc. is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. Its products include AVONEX, TYSABRI, FAMPYRA, RITUXAN and FUMADERM. AVONEX product is indicated for the treatment of patients with relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. TYSABRI product is indicated for the treatment of relapsing forms of MS as a monotherapy to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. This product is also used for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation. FAMPYRA product is indicated for the improvement of walking ability in adult patients with MS who have walking disability. FUMADERM product is only approved in Germany and is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom topical therapy is ineffective. RITUXAN product is indicated for treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens; and for previously untreated follicular. Biogen Idec was founded on November 12, 2003 and is headquartered in Weston, MA.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Lifeline to Patients

In the introductory video of the series, listen to PO&T employees and leadership talk about the group's scope and its commitment to patients.

Biogen Idec, Inc. video

Lifeline to Patients

Biogen Idec, Inc. video

Care Deeply Volunteer Day

Biogen Idec, Inc. video

Developing Biologic Drugs

Executives

George A. Scangos, Ph.D., Chief Executive Officer
George A. Scangos, Ph.D., is our Chief Executive Officer and a member of the Board of Directors of Biogen Idec and has served in these positions since June 2010. He joined the company from Exelixis, Inc., where he served as President and CEO and a director since October 1996. From September 1993 to October 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research and development, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University. He is also a member of the Board of Visitors of the University of California, San Francisco School of Pharmacy, and the National Board of Visitors of the University of California, Davis School of Medicine. He is currently an Adjunct Professor of Biology at Johns Hopkins. Dr. Scangos holds a B.A. in Biology from Cornell University, a Ph.D. in Microbiology from the University of Massachusetts, and was a Jane Coffin Childs Post-Doctoral Fellow at Yale University.
Susan H. Alexander, Executive Vice President, General Counsel and Corporate Secretar
Susan H. Alexander is our Executive Vice President, General Counsel and Corporate Secretary and has served in these positions since January 2006. Prior to that, Ms. Alexander had served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corp. since September 2003. From June 2001 to September 2003, Ms. Alexander served as General Counsel of IONA Technologies. From January 1995 to May 2001, Ms. Alexander served as Counsel at Cabot Corp. Prior to that, Ms. Alexander was a partner of the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.
Paul J. Clancy, Chief Financial Officer
Paul J. Clancy is our Executive Vice President and Chief Financial Officer and has served in these positions since August 2007. Mr. Clancy has also served as Senior Vice President of Finance and Vice President of Business Planning at Biogen Idec. Prior to the merger, Mr. Clancy had served as Vice President of Portfolio Management at Biogen Inc. since 2003. He joined the company in 2001 as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo, serving in a range of financial and general management positions including most recently Vice President and General Manager of their Great West Business Unit.

News & Analysis

You may also be interested in: